India government launches its own brand to sell cheap generic drugs

India is well known to be one of the “workhorse” in generic production. Despite the comparable reasonably priced drugs in global market, the lower income population is still having difficulty in affording them during treatments. As an initiative to provide more holistic healthcare services for all, Indian government has decided to step in and control generic prices by purchasing and …

Out with the old for cancer treatment?

Today is #WorldCancerDay and it strikes me that it is great to see all of the developments in cancer treatments within the scientific community. The way in which we develop medicines is changing, and now everywhere you look you see information about ‘personalised’ or ‘precision’ medicine. One of the areas which is being hailed as a key disease group which …

Emerging Markets

Strategies for bioclusters in emerging markets

In a new study published in Nature Reviews Drug Discovery, Dr. Ajay Gautam at AstraZeneca has proposed a framework for innovation bioclusters across the emerging markets. By analyzing 8 Chinese bioclusters according to their academic and entrepreneurial activity, Dr. Gautam has classified bioclusters as emerging Innovation Leaders, Untapped Talent, Niche Hubs and Aspiring clusters. He has further proposed investment policies …

Patient, Registries, Evidence, Value, Evidence Europe

How can patient registries add value to evidence based decision making?

At Evidence EU 2014, Dr. Päivi Hämäläinen, Director of Department of Information, National Institute of Health and Welfare, Finland, gave a presentation “How can patient registries add value to evidence based decision making?” Dr. Päivi Hämäläinen’s presentation depicts her theoretical vision: data is created during patient visits to care and can be secondarily used for research, planning and decision making. Download and …

ed schoonveld, price of global health, pharma pricing, pharma, health economics, pharma pricing and market access europe

The Price of Global Health

We recently had a chance to catch up with Ed Schoonveld, author of ‘The Price of Global Health,’ Managing Principal and Market Access & Pricing Leader with ZS, to gain his insights into issues affecting the industry, the latest release of ‘The Price of Global Health (2nd Edition),’ and his involvement with the upcoming World Pharma Pricing & Market Access Congress. …

The Netherlands: In the midst of change

  At the World Pharma Pricing & Market Access Congress 2014 conference, Dr Martin van der Graaff, Secretary, Reimbursement Committee, CVZ gave the presentation: “The Netherlands: In the mi(d)st of change” Download and learn: Organisational change in CVZ End of an era: Policy rules and outcomes research First results and experiences with CED Preliminary criteria for prioritizing inpatient drugs Priorities Are …

NHS faces backlash over Cancer Drugs Fund treatments changes

NHS England announced this week a decision to reassess 42 drugs that are available as part of the Cancer Drugs Fund. The decision comes as a result of current spending expected to be £100m over the initial budget of £280m for this financial year. With the current system viewed as unsustainable, price caps have been brought in for the first time …

Disease, Value, Registries, Decision making, Evidence, Evidence Europe

How Can Disease Registries Add Value to Evidence Based Decision Making?

At Evidence EU 2014, Steve Cunningham Consultant & Honorary Reader in Paediatric Respiratory Medicine, NHS, gave a presentation on “How Can Disease Registries Add Value to Evidence Based Decision Making?” Download and learn:  Case Identifier Registry Detailed Case Registry Large Disease Registry Current Definitions of Evidence Quality Evidence Quality -GRADE System Detailed Observational Data Download presentation Found this interesting? Join us at …